Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
In this study the investigators will evaluate the uptake of 89Zirconium labeled cetuximab in
extra-hepatic colorectal metastases. The investigators hypothesize that uptake of
89Zr-cetuximab is required for response to cetuximab. If no uptake is present the
investigators will escalate the dose cetuximab and repeat the 89Zr-cetuximab PET.
The investigators will evaluate the clinical benefit rate of cetuximab in the patients with
and without uptake. The ultimate goal is to create a selection tool that can predict response
of cetuximab.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
VU University Medical Center
Collaborators:
Radboud University University Medical Center Groningen